Zorevunersen

A clinical trial of zorevunersen at Sheffield Children's Hospital has dramatically improved the lives of children with Dravet syndrome, a rare form of epilepsy affecting approximately one in 15,000 babies.

The first quarter of 2025 witnessed significant biotech partnership activity, with Eli Lilly, AstraZeneca, and Novo Nordisk emerging as top collaborators in deals worth billions across small molecules, antibodies, and RNA therapeutics.

Biogen has entered a strategic partnership with Stoke Therapeutics, investing up to $550 million for ex-North American rights to zorevunersen, a promising treatment for Dravet syndrome.

Rapport Therapeutics' RAP-219 achieved target receptor occupancy within five days, supporting its potential for treating CNS disorders.

Johnson & Johnson's posdinemab, a monoclonal antibody targeting phosphorylated tau, has received FDA Fast Track designation for early Alzheimer's treatment.